ScholarIQanswers from OpenAlex & ORCID
David A. D’Alessio
ResearcherPublications, citations & collaboration network
David A. D’Alessio is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does David A. D’Alessio have?
ScholarIQindexed works
David A. D’Alessio has 360 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does David A. D’Alessio have?
ScholarIQcitation count
David A. D’Alessio has 34,354 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of David A. D’Alessio?
ScholarIQh-index
David A. D’Alessio has an h-index of 93 in OpenAlex.
What is the i10-index of David A. D’Alessio?
ScholarIQi10-index
David A. D’Alessio has an i10-index of 239 in OpenAlex.
What is the ORCID of David A. D’Alessio?
ScholarIQorcid
The ORCID for David A. D’Alessio is on the source record.
What is the OpenAlex record for David A. D’Alessio?
ScholarIQopenalex
The OpenAlex for David A. D’Alessio is on the source record.
What are the most-cited papers on David A. D’Alessio?
ScholarIQmost cited works
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, David A. D’Alessio, Judith Fradkin, Walter N. Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Απόστολος Τσάπας, Deborah J. Wexler, John B. Buse
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, David A. D’Alessio, Judith Fradkin, Walter N. Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Απόστολος Τσάπας, Deborah J. Wexler, John B. Buse
Ghrelin
Timo D. Müller, Rubén Nogueiras, Mark L. Andermann, Zane B. Andrews, Stefan D. Anker, Jesús Argente, Rachel L. Batterham, S.C. Benoit, C. Y. Bowers, Fabio Broglio, Felipe F. Casanueva, David A. D’Alessio, Inge Depoortere, Allan Geliebter, Ezio Ghigo, Philip A. Cole, Michael A. Cowley, D. E. Cummings, Alain Dagher, Sabrina Diano, Suzanne L. Dickson, Carlos Diéguez, Riccarda Granata, Harvey J. Grill, Kelly Grove, Kirk M. Habegger, Kristy M. Heppner, Mark L. Heiman, Laura M. Holsen, Birgitte Holst, Akio Inui, J-O Jansson, Henriette Kirchner, Márta Korbonits, Blandine Laferrère, C.W. LeRoux, Miguel López, Sophie Morin, Michiko Nakazato, Ralf Nass, Diego Pérez–Tilve, Paul T. Pfluger, Thue W. Schwartz, Randy J. Seeley, Mark W. Sleeman, Yuxiang Sun, Lori Sussel, Jenny Tong, Michael O. Thorner, A. J. van der Lely, L. H. T. Van der Ploeg, Jeffrey M. Zigman, Masayasu Kojima, Kenji Kangawa, R G Smith, Tamás L. Horváth, M. Tschöp
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
Tamer Coşkun, Kyle W. Sloop, Corina Loghin, Jorge Alsina‐Fernandez, Shweta Urva, Krister Bokvist, Xuewei Cui, Daniel A. Briere, Over Cabrera, William C. Roell, Uma Kuchibhotla, Julie S. Moyers, Charles Benson, Ruth E. Gimeno, David A. D’Alessio, Axel Haupt